Words from CEO Dave Elsley >> From LinkedIn today >>
We are extremely pleased with the FDA’s favourable decision to grant clearance for our important clinical study in acute myocarditis to proceed in the U.S. This potentially devastating condition remains a leading cause of sudden cardiac death in children and young healthy adults. Sadly, there is no recognized standard of care available to the thousands of patients affected each year.
Since the FDA approved the first cannabidiol medicine in 2018 for
rare forms of epilepsy, the lives of thousands of children have been
significantly improved. We are grateful to now be in a position to pursue a similar mission to improve the lives of children and young adults suffering from inflammatory heart disease. We believe this effort will not only potentially improve and save lives but will also reward our shareholders whose loyal support has made all of this possible.
I would also like to thank the Cardiol Team for their tireless
efforts working round the clock to reach this important milestone ahead of schedule.